Unparalleled chemistry results for the fourth quarter of FY 2021-22 and FY 2021-22 આવક Revenue of ₹ 10,660 million in FY 2021-22; 31.46% growth year on year
Profit after tax payments in fiscal year 2021-22 1,522 million; Growth of 116.48%
Surat, India’s leading custom synthesis and specialty chemical company Anupam Rasayan India Limited (BSE-543275, NSE-ANURAS, ISIN: INE930P01018) has announced its financial results for the quarter ended March 31, 2022 and the financial year ended.
Financial results for the quarter ended March 31, 2022:
Revenue for the fourth quarter of FY2021-22 was ₹ 3,172 million, an increase of 17% year-on-year from ₹ 2,717 million in the fourth quarter of FY2021-21.
EBITDA (including other income) reached ₹ 969 million in the fourth quarter of FY2021-22, an increase of 48% year-on-year from ₹ 655 million in the fourth quarter of FY2021-21.
Profit after tax payments in the fourth quarter of FY2021-22 was ₹ 461 million, an increase of 108% year-on-year from ₹ 221 million in the fourth quarter of FY2021-21.
Financial results for the 12 months ended March 31, 2022:
Revenue reached ₹ 10,660 million in FY2021-22, an increase of 31% year-on-year from ₹ 8,109 million in FY2021-21.
EBITDA (including other income) reached ₹ 3.121 million in FY2021-22, an increase of 42% year-on-year from ₹ 2.202 million in FY2021-21.
Profit after tax payments were ₹ 1,522 million in FY2021-22, up 116 percent year-over-year from ₹ 703 million in FY2021.
Anand Desai, Managing Director, Anupam Rasayan, said, “I am pleased to announce that the year has proved to be a good one for us with a growth of 29% in our total revenue, mainly due to high volume growth. With new LOIs and the replacement of old long-term contracts, visibility for sales growth will become clearer in the coming years. ”
He added: “In addition, our entry into fluorination chemicals will take us to the next stage of growth, in which our position is strengthened by the successful acquisition of 26 per cent stake in Tenfac. Through this acquisition, we look forward to the backward integration of our supply chain into this vertical and focus on high value – high margin product molecules, which will further accelerate our margins. “